Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) announced that its board of directors passed a resolution on February 9, 2026 to propose an H Share Award Scheme. The plan is subject to shareholder approval at an extraordinary general meeting (EGM). According to the announcement, up to 5.0% of the company’s total issued shares (excluding treasury shares) as of the adoption date—equivalent to 8,379,890 H shares—may be awarded under the scheme.

Under the proposed framework, existing H shares are to be acquired through on- and off-exchange transactions. The stated purpose is to recognize the contribution of selected participants and provide incentives for their continued service. The scheme will be effective for 10 years from the date of approval. After termination, any remaining unvested shares will revert to the trust fund and be disposed of within a specified period, with net proceeds remitted to the company.

The board clarified that the scheme constitutes a share scheme with existing shares under Chapter 17 of the Listing Rules, requiring relevant disclosure but not shareholder approval under the Listing Rules. However, shareholder approval is mandated under the company’s articles of association before the plan can take effect. The board will send out a circular with further details and a formal meeting notice in due course.